Aceragen | IDRA - Betriebsergebnis



Betriebsergebnis Veränderung Datum
Abbott USD 2.25B 73M 2025-12
Agenus USD 14.4M 19.26M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Alterity Therapeutics Limited AUD -7.77M 2.99M 2023-06
Amgen USD 3.96B 464M 2025-12
Biogen USD 659.6M 192.2M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Cipla INR 9.77B 6.21B 2025-12
Clal Biotechnology ILS -1.74M 7.46M 2022-12
Compugen USD 56.04M 63.93M 2025-12
CSL USD 2.64B 1.97B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Grifols EUR 320.55M 91.01M 2025-12
Merck USD 6.24B 318M 2025-12
Nektar Therapeutics USD -34.34M 15.43M 2024-09
Pfizer USD 4.65B 3.99B 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
X T L Biopharmaceuticals USD -812K 48K 2024-12